Vietnam’s Gene Solutions receives investment from Singapore’s August Global Partners
August Global Partners (AGP), a Singapore-based healthcare investor, is making a proprietary funding round investment in Gene Solutions (GS), a genomic testing company based in Vietnam.
The two have signed a memorandum of understanding (MoU) for the partnership, according to a statement from Gene Solutions.
By developing a suite of artificial intelligence (AI) technologies that include a clinical database, large language models (LLM), multi-omics insights, and a scientific knowledge base, GS will push the limits of next-generation sequencing (NGS) services and facilitate the wider adoption of precision medicine and targeted therapeutics in Asia under the terms of the Memorandum of Understanding.
Through years of clinical research collaborations and DNA testing experience in the oncology and reproductive health verticals, GS developed the AI suite, known as DNAsphere.AI.
By using this AI suite, GS can lower sequencing costs and greatly enhance test performance, which will increase the availability of customized solutions.
By giving them access to top-notch research resources and local partners, AGP, which is investing in GS through a proprietary funding round, will help them improve the performance of their oncology solutions.
By doing so, GS will be able to apply the DNAsphere.AI suite to customized cancer treatment applications and further validate the accuracy of its tests.
Notably, GS is currently bringing its line of personalized cancer care products to a worldwide audience.
Their well-known cancer monitoring tests (K-TRACK) and early cancer detection (SPOT-MAS) are among them.
The company recently announced the release of single-cancer early detection (SCED) tests to improve early cancer screening adherence in asymptomatic populations. These tests were created using AI-driven ctDNA technology.
Cell therapies, neoantigen vaccines, and targeted cancer medications are just a few of the innovative cancer treatments that GS is currently working on with top biopharma companies.
“Cancer is a debilitating disease that has impacted many of our loved ones or ourselves profoundly. This partnership is a pivotal milestone in our company’s mission to provide advanced and accessible oncology solutions,
“By combining our genomic expertise with AGP’s investment and network, we aim to make blood-based cancer screening and treatment monitoring tests more accurate and more affordable,” said Dr. Nguyen Hoai Nghia, Chief Executive Officer and Chairman of GS.
A biotech business based in Asia, GS is well-known for its cutting-edge oncology and reproductive solutions.
In the area, the company has supplied more than 2,000,000 cell-free DNA tests, including more than 20,000 multi-cancer early detection tests and more than 60,000 tumor profiling tests.
